Evaluation of the Effects of Intravitreal Application of the Ozurdex Implant in Patients with Macular Edema due to Retinal Vein Occlusion
Authors:
Martin Lada; Renata Ženíšková; Zuzana Hradcová; Jana Schützová; Jan Tesař; Jan Grygar; Jan Havlik; Martin Šín
Authors‘ workplace:
Oční klinika 1. LF a ÚVN, Praha
Published in:
Čes. a slov. Oftal., 82, 2026, No. 5, p. 263-270
Category:
Original Article
doi:
https://doi.org/10.31348/2026/8
Overview
Aims: A retrospective evaluation of the outcomes and safety of the Ozurdex implant in patients with cystoid macular edema (CME) due to retinal vein occlusion (RVO).
Material and Methods: A retrospective analysis of 14 eyes (10 male patients, 4 female patients) treated with the Ozurdex implant at the application center of the Department of Ophthalmology at the Military University Hospital, with the indication of RVO. The period of monitored applications was from 2022 to 2024. Patients were followed up every two months for at least one year after the first application. The primary efficacy parameters assessed were: Best-corrected visual acuity (BCVA), Central retinal thickness (CRT), Intraocular pressure (IOP), Changes in the diameter of intraretinal cysts (IR), as the main OCT biomarker.
Results: At the first follow-up, two months after Ozurdex application, there was a statistically significant functional improvement, with an average increase of 4.7 letters ETDRS letters (p = 0.042). Six months after application, the average BCVA reached 58 letters ETDRS letters. CRT decreased by an average of 100 µm two months after the initial DEX implant. The highest and statistically significant increase in IOP (p = 0.008) was recorded two months after the application (with an average value of 20.9 mmHg).
Conclusion: Our results indicate that Ozurdex is a safe and effective second-line treatment for macular edema (ME) due to RVO. In our group, the best functional and anatomical results were achieved two months after application. By the fourth month, a decline in BCVA and an increase in CRT were observed. Between the fifth and sixth month, retreatment was necessary in some patients. Additionally, we confirmed that the greatest rise in IOP occurred two months post-application, which resolved spontaneously by the sixth month. In four patients, IOP values above 30 mmHg were recorded during follow-up, and the intraocular pressure was managed with medication.
Keywords:
Ozurdex – dexamethasone (DEX) – macular edema (ME) – retinal vein occlusion (RVO) – central retinal vein occlusion (CRVO) – branch retinal vein occlusion (BRVO)
Sources
1. Studnička J, Němčanský J, Vysloužilová D, Ernest J, Veith M, Němec P. Retinal Vein Occlusion Guidelines, Cesk Slov Oftalmol. 2024;80(6):298-305.
2. Schreiberova Z, Rehak J, Babkova B, et al. Hypertension, hyperlipidaemia and thrombophilia as the most common risk factors for retinal vein occlusion in patients under 50 years. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Mar;168(1):44-49. Epub 2022 Aug 29. doi: 10.5507/bp.2022.036
3. Studnička J, Němčanský J, Stěpanov A. Sítnice: komplexní přehled od anatomie k chirirgické léčbě. Praha: Grada Publishing, 2023. ISBN 978-80-271-3586-8
4. Eissa M, Kalogeropoulos D, Evans W, Arora R, Lotery AJ. Efficacy of Ozurdex implants as second-line therapy for non-responders to anti-VEGF in retinal vein occlusion-associated macular edema: a retrospective cohort study. Ir J Med Sci. 2025 Apr;194(2):745-750. Epub 2025 Jan 24. doi: 10.1007/s11845-025-03881-z
5. Zou W, Du Y, Ji X, et al. Comparison of the efficiency of anti-VEGF drugs intravitreal injections treatment with or without retinal laser photocoagulation for macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis. Front Pharmacol. 2022 Jul 22;13 : 948852. doi: 10.3389/fphar.2022.948852
6. Hattenbach LO, Feltgen N, Bertelmann T, et al. COMRADE-B Study Group. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. 2018 Feb;96(1):e10-e18. doi: 10.1111/aos.13381
7. Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of Corticosteroids for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):1-12. doi: 10.1167/iovs.17-22259 8. Giles AJ, Hutchinson MND, Sonnemann HM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-5
9. Šín M, Šínová I, Chrapek O, et al. The effect of pars plan vitrectomy on oxygen saturation in retinal vessels – a pilot study. Acta Ophthalmol. 2014 Jun;92(4):328-331. Epub 2013 Jul 15. doi: 10.1111/aos.12238
10. Haller JA, Bandello F, Belfort R Jr, et al. OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. Epub 2010 Apr 24. doi: 10.1016/j.ophtha.2010.03.032
11. Gale R, Gill C, Pikoula M, et al. Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections. Br J Ophthalmol. 2021 Nov;105(11):1571-1576. Epub 2020 Sep 22. doi: 10.1136/bjophthalmol-2020-317306
12. Liang X, Shen B, Ou Z, An H, Li L. Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion. Front Med (Lausanne). 2022 Sep 12;9 : 930508. doi: 10.3389/ fmed.2022.930508
13. Mudroch T, Hrevuš M, Karhanová M, Řehák J, Marešová K. Intravitreal Dexamethasone Implant in the Treatment of Diabetic Macular Edema Focusing on the Role of OCT Biomarkers. Cesk Slov Oftalmol. 2025;81(1):16-23. doi: 10.31348/2024/29
14. Garweg JG, Zandi S. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1257-1265. Epub 2016 May 13. doi: 10.1007/s00417-016 - 3350-x
15. Hoerauf H, Feltgen N, Weiss C, et al. COMRADE-C Study Group. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. Am J Ophthalmol. 2016 Sep;169 : 258-267. Epub 2016 May 7. doi: 10.1016/j.ajo.2016.04.020
16. Munk MR, Somfai GM, de Smet MD, et al. The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int J Mol Sci. 2022 Jul 8;23(14):7585. doi: 10.3390/ ijms23147585
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2026 Issue 5
Most read in this issue
- Evaluation of the Effects of Intravitreal Application of the Ozurdex Implant in Patients with Macular Edema due to Retinal Vein Occlusion
- Retinal Nerve Fiber Layer and Ganglion Cell Complex Thickness Analysis in Treatment – Naive Glaucoma Patients
- The Role of Prophylactic Topical Administration of Antibiotics in Uncomplicated Cataract Surgery in the Era of Intracameral Antibiotics. Opinion Article
- Customized Cryotherapy for Ocular Salvage in Descemetocele and Iris Prolapse: A 17-Year Retrospective Study